Results 1 to 10 of about 3,844,628 (256)

Influenza in today: direct-acting antiviral therapy

Медицинский совет, 2015
Influenza is an acute infectious disease caused by influenza virus (Orthomyxoviridae family) which affects up to 15% of the world population in the cold season.
T. V. Sologub
doaj   +2 more sources

Direct Acting Antiviral Drugs: Pharmacokinetics and Drug-Drug Interactions

Archives of Pharmaceutical Sciences Ain Shams University, 2022
Hepatitis C (HCV) is a widespread health issue, which can lead to hepatic cirrhosis, liver failure, and liver cancer. Nearly 2% of the world's population or > 185 million people are chronically infected with HCV; the management of HCV and the rate of ...
Marina Barakat, Sara Wahdan, Azza Awad, Ebtehal El-Demerdash Zaki   +3 more
doaj   +1 more source

Efficacy and safety of direct-acting antivirals for HCV in patients with extrahepatic malignancies: real-life experience

Egyptian Liver Journal, 2022
Background Outcome of HCV treatment with direct antiviral agents in malignant patients is questionable. The aim is to assess the safety and efficacy of DAAs in treatment of chronic HCV patients who received chemotherapy for malignancies.
Mira Atef, Rasha Eletreby, Mohamed Abdallah, Rasha Salama, Wafaa Elakel, Mohamed Hassany, Wael Abdel-Razek, Yehia El Shazly, Wahid Doss, Gamal Esmat   +9 more
doaj   +1 more source

Acute reversible rhabdomyolysis during direct-acting antiviral hepatitis C virus treatment: a case report

Journal of Medical Case Reports, 2021
Introduction Treatment of hepatitis C infection has evolved dramatically since 2011. Previous conventional therapy with interferon and ribavirin used to have a low sustained virological response rate of less than 40%.
Abdulrahman Qatomah, Majidah Bukhari, Edward Cupler, Hosam Alardati, Mohammad Mawardi   +4 more
doaj   +1 more source

Clinical outcomes of patients with chronic hepatitis C after generic direct-acting antiviral treatments in Vietnam: A retrospective analysis

Asian Pacific Journal of Tropical Medicine, 2020
Objective: To evaluate the outcomes of generic direct-acting antiviral treatments for chronic hepatitis C in Vietnam. Methods: The medical records of 522 patients (median 45 years; Female, 25.3%) with chronic hepatitis C treated at a tertiary hospital in
Huong TT Vu, Azumi Ishizaki, Quynh T Nguyen, Huyen N Nguyen, Hoi T Le, Kinh V Nguyen, Hiroshi Ichimura   +6 more
doaj   +1 more source

Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence

Egyptian Liver Journal, 2020
Background The impact of direct-acting antivirals (DAAs) remains a debate, whether they accelerate the recurrence rate of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) after curative therapy.
Nevine Ibrahim Musa, Inas Elkhedr Mohamed, Ahmed Samir Abohalima   +2 more
doaj   +1 more source

Direct-acting antiviral therapy of chronic hepatitis C improves liver fibrosis, assessed by histological examination and laboratory markers

Journal of the Formosan Medical Association, 2021
Background/Purpose: Direct-acting antiviral agents achieve sustained virological response in most chronic hepatitis C patients. However, histological responses are not consistent among all patients.
Chun-Han Cheng, Chia-Ying Chu, Huan-Lin Chen, I-Tsung Lin, Chia-Hsien Wu, Yuan-Kai Lee, Ping-Jen Hu, Ming-Jong Bair   +7 more
doaj   +1 more source

Ocular manifestations and treatment safety in hepatitis C patients undergoing direct-acting antiviral therapy: a prospective cohort study [PDF]

Revista Brasileira de Oftalmologia
Objective: To report the frequency of ocular manifestations in patients undergoing direct-acting antiviral therapy and assess treatment safety based on outcomes; to identify demographic variables associated with hepatitis C virus infection; evaluate ...
Guilherme Thomé de Carvalho, Carlos Eduardo Brandão Mello, Kelma Macedo Pohlmann Simões, Mário Martins dos Santos Motta, Max Kopti Fakoury, Bruno Vasconcelos Coimbra, Laura Gomes Nunes Melo, Flávio Mac Cord Medina   +7 more
doaj   +1 more source

Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience

The Turkish Journal of Gastroenterology, 2020
Background/Aims: This study aimed to evaluate the real-life efficacy and tolerability of direct-acting antiviral treatments for patients with chronic hepatitis C (CHC) with/without cirrhosis in the Turkish population.
Bülent Değertekin, Mehmet Demir, Ulus S. Akarca, Haluk Tarık Kani, Enver Üçbilek, Emre Yıldırım, Fatih Güzelbulut, Ayhan Balkan, Sezgin Vatansever, Nilay Danış, Melek Demircan, Aliye Soylu, Serkan Yaras, Aysun Kartal, Ayşe Kefeli, Feyza Gündüz, Kendal Yalçın, Elife Erarslan, Murat Aladağ, Murat Harputluoğlu, Ayşegül Özakyol, Tuncer Temel, Mesut Akarsu, Hale Sümer, Mete Akın, Bülent Albayrak, İlker Sen, Hüseyin Alkım, Ahmet Uyanıkoğlu, Kader Irak, Sinem Öztaşkın, Çağrı Burak Uğurlu, Şevkican Güneş, Selim Gürel, Kenan Nuriyev, İsmail İnci, Sabite Kaçar, Dinç Dinçer, Levent Doğanay, Hüseyin Savaş Göktürk, Ali Mert, Arif Mansur Coşar, Hakan Dursun, Roni Atalay, Sabiye Akbulut, Yasemin Balkan, Hayrettin Koklu, Halis Şimşek, Osman Özdoğan, Mehmet Çoban   +49 more
doaj   +1 more source

Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma

Viruses, 2022
Background: The benefits of hepatitis C virus (HCV)eradication for hepatocellular carcinoma (HCC) patients in Barcelona Clinic Liver Cancer (BCLC) stage B/C remain uncertain.
Shou-Wu Lee, Li-Shu Chen, Sheng-Shun Yang, Yi-Hsiang Huang, Teng-Yu Lee   +4 more
doaj   +1 more source